Figures & data
Table 1 Distribution of the IAI and UTI pathogens in China during 2016–2017
Table 2 Distribution of ESBL-producing strains in China during 2016–2017
Table 3 ESBL positivity and antibiotic susceptibility rates (%) for E. coli and K. pneumoniae isolates from HA vs CA IAIs & UTIs
Table 4 ESBL producing E. coli and K. pneumoniae susceptibility rates from Gram-negative IAI & UTI isolates obtained from ICU and non-ICU units
Figure 1 Susceptibilities of E. coli and K. pneumonia isolates from HA and CA IAIs and UTIs. (A) E. coli isolates from IAIs, (B) E. coli isolates from UTIs, (C) K. pneumonia isolates from IAIs, and (D) K. pneumonia isolates from UTIs.
Abbreviations: HA, hospital-acquired; CA, community-acquired; IAI, intraabdominalinfection; UTI, urinary tract infection; IPM: Carbapenems: Imipenem; ETP, Ertapenem; AMK, Aminoglycoside: Amikacin; TZP, Piperacillin-Tazobactam; FOX, Cephalosporins: Cefoxitin, CAZ, Ceftazidime, CRO, Ceftriaxone, CTX, Cefotaxime, FEP, Cefepime; LVX, Fluoroquinolones: Levofloxacin; CIP, Ciprofloxacin.
Figure 2 Percentages of susceptible K. pneumoniae IAI and UTI isolates to IMP, ETP, AMK, and TZP from 2015 to 2017.
Abbreviations: IAI, intraabdominalinfection; UTI, urinary tract infection; IPM: Carbapenems: Imipenem; ETP, Ertapenem; AMK, Aminoglycoside: Amikacin; TZP, Piperacillin-Tazobactam.
Table S1 ESBL positivity and antibiotic susceptibility rates (%) for P. mirabilis and K. oxytoca isolates combined in HA vs CA IAIs and UTIs